Get the Stockscreener App
0.2494
12.12%
-0.0349
Cosmos Health Inc stock is traded at $0.2494, with a volume of 1.18M.
It is down -12.12% in the last 24 hours and down -28.35% over the past month.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
See More
Previous Close:
$0.2843
Open:
$0.2749
24h Volume:
1.18M
Relative Volume:
1.33
Market Cap:
$13.05M
Revenue:
$65.27M
Net Income/Loss:
$-19.15M
P/E Ratio:
-0.4017
EPS:
-0.6208
Net Cash Flow:
$-12.43M
1W Performance:
-18.46%
1M Performance:
-28.35%
6M Performance:
-63.13%
1Y Performance:
-46.93%
1-Day Range:
$0.2464
$0.2749
1-Week Range:
$0.2464
$0.3083
52-Week Range:
$0.2464
$1.32
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM vs MCK, COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.2494 | 14.88M | 65.27M | -19.15M | -12.43M | -0.6208 |
MCK
Mckesson Corp
|
759.25 | 90.72B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
263.08 | 51.51B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
199.36 | 46.66B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
72.98 | 8.34B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.55 | 1.37B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cosmos Health Inc Stock (COSM) Latest News
Cosmos Health (COSM) Reports Strong Q1 2026 Revenue Growth - GuruFocus
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year - Investing.com
Cosmos Health trims $4.5M debt, eyes U.S. nutraceuticals push after record Q1 - Stock Titan
Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary - TradingView
Cosmos Health (NASDAQ: COSM) posts Q1 loss and issues going‑concern warning - Stock Titan
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt P - ACCESS Newswire
Cosmos Health Company Profile & Introduction - Moomoo
COSM Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Cosmos Health Inc stock (US22143K1016): volatility after reverse split and uplisting plans draw inve - AD HOC NEWS
Cosmos Health Inc.Common Stock (NQ: COSM - FinancialContent
[NT 10-Q] Cosmos Health Inc. SEC Filing - Stock Titan
Cosmos Health (COSM) Engages European Investment Bank for R&D Fi - GuruFocus
Cosmos Health stock (US22143K1016): Pursues €25M EIB financing for R&D - AD HOC NEWS
Cosmos Health pursues €25M EIB financing for R&D program By Investing.com - Investing.com South Africa
Cosmos Health pursues €25M EIB financing for R&D program - Investing.com
EU bank review could unlock €25M for Cosmos Health drug R&D - Stock Titan
Cosmos Health regains compliance with Nasdaq’s listing rule - MSN
Cosmos Health (COSM) Withdraws Registration Statement for Public Offering - GuruFocus
TradingKey - TradingKey
Cosmos Health stock (US22143K1016): Fort18 launch targets $3.2M revenue boost - AD HOC NEWS
Cosmos Health withdraws SEC registration statement - Investing.com UK
Cosmos Health withdraws SEC registration statement By Investing.com - Investing.com South Africa
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 - ACCESS Newswire
Cosmos Health scraps public offering, pulls SEC registration - Stock Titan
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months - Digital Journal
[RW] Cosmos Health Inc. SEC Filing - Stock Titan
Men's stamina supplement Fort18 targets $3.2M U.S. sales - Stock Titan
Cosmos Health Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
COSM introduces new product for sexual health - MSN
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed - ACCESS Newswire
Cosmos Health(COSM) Stock Options Chain | Quotes & News - Moomoo
Cosmos Health Introduces the "18 Series" in the United StatesA Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products - Quantisnow
COSM Stock Price, Quote & Chart | COSMOS HEALTH INC (NASDAQ:COSM) - ChartMill
Number of shareholders of Cosmos Health Inc. – NASDAQ:COSM - TradingView
Cosmos Health launches Fort18 men’s wellness supplement in U.S. By Investing.com - Investing.com Australia
Cosmos Health launches Fort18 men’s wellness supplement in U.S. - Investing.com UK
Cosmos Health Introduces Fort18 in the United StatesA Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness - ACCESS Newswire
Cosmos Health enters men's wellness as U.S. market heads to $1.93B - Stock Titan
Cosmos Health (COSM) price target increased by 50.00% to 4.59 - MSN
Cosmos Health (COSM) Projects Significant Revenue Growth with Cu - GuruFocus
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cosmos Health Inc Stock (COSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.41 |
291,262 |
120,000 |
8,473,382 |
| Siokas Grigorios | Chief Executive Officer |
Jan 23 '26 |
Buy |
0.50 |
90,325 |
45,000 |
8,182,120 |
| Siokas Grigorios | Chief Executive Officer |
Jan 20 '26 |
Buy |
0.50 |
353,321 |
175,000 |
8,091,795 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '26 |
Buy |
0.45 |
493,495 |
220,000 |
7,738,474 |
| Siokas Grigorios | Chief Executive Officer |
Jan 12 '26 |
Buy |
0.50 |
113,185 |
57,000 |
7,244,979 |
| Siokas Grigorios | Chief Executive Officer |
Jan 08 '26 |
Buy |
0.52 |
156,190 |
81,000 |
7,131,794 |
| Siokas Grigorios | Chief Executive Officer |
Jan 07 '26 |
Buy |
0.52 |
124,880 |
65,000 |
6,975,604 |
| Siokas Grigorios | Chief Executive Officer |
Jan 06 '26 |
Buy |
0.54 |
133,953 |
72,000 |
6,850,724 |
| Siokas Grigorios | Chief Executive Officer |
Dec 19 '25 |
Buy |
0.49 |
88,314 |
43,000 |
6,716,771 |
| Siokas Grigorios | Chief Executive Officer |
Dec 15 '25 |
Buy |
0.42 |
168,472 |
70,000 |
6,628,457 |
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):